22nd Century Group (XXII) Expected to Announce Quarterly Earnings on Friday

22nd Century Group (NASDAQ:XXII) is expected to be releasing its Q1 2026 results before the market opens on Friday, May 15th. Analysts expect 22nd Century Group to post earnings of ($1.20) per share and revenue of $4.61 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

22nd Century Group (NASDAQ:XXII) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($5.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($3.87). 22nd Century Group had a negative net margin of 25.34% and a negative return on equity of 84.37%. The firm had revenue of $4.11 million for the quarter, compared to the consensus estimate of $4.61 million.

22nd Century Group Stock Down 2.2%

XXII opened at $0.58 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.12. The company’s 50-day moving average is $2.52 and its 200 day moving average is $9.28. 22nd Century Group has a fifty-two week low of $0.51 and a fifty-two week high of $434.67. The firm has a market capitalization of $418,392.00, a P/E ratio of 0.00 and a beta of 0.77.

Institutional Trading of 22nd Century Group

A hedge fund recently raised its stake in 22nd Century Group stock. Anson Funds Management LP boosted its stake in 22nd Century Group, Inc (NASDAQ:XXII) by 677.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 763,212 shares of the biotechnology company’s stock after acquiring an additional 665,000 shares during the period. Anson Funds Management LP owned 149.65% of 22nd Century Group worth $588,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 18.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of 22nd Century Group from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.